ARG
Type 2 Diabetes
Avid RadiopharmaceuticalsSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
142 Active assets in the Type 2 Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide RenJi Hospital | Phase 4 | BBB |
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Cotadutide AstraZeneca | Phase 2 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
ARG is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →